Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates

G. P. Allaway, K. L. Davis-Bruno, G. A. Beaudry, E. B. Garcia, E. L. Wong, A. M. Ryder, K. W. Hasel, M. C. Gauduin, R. A. Koup, J. S. McDougal, P. J. Maddon

Research output: Contribution to journalArticle

215 Citations (Scopus)

Abstract

CD4-IgG2 is a novel fusion protein comprising human IgG2 in which the Fv portions of both heavy and light chains have been replaced by the V1 and V2 domains of human CD4. This tetrameric protein is being developed as an immunoprophylactic agent to reduce the probability of infection following HIV-1 exposure, in settings such as occupational or perinatal exposure to the virus. CD4-IgG2 has been expressed in Chinese hamster ovary cells and is secreted as a fully assembled heterotetramer. The protein binds with nanomolar affinity to purified gp120 from both a laboratory-adapted strain and a primary isolate of HIV-1. Pharmacokinetic studies in rabbits demonstrated that CD4-IgG2 has a plasma terminal half-life greater than 1 day, compared with 15 min for soluble CD4 (sCD4). CD4-IgG2 does not bind to Fc receptors on the surface of U937 monocyte/macrophage cells. Compared to molecules that incorporate the Fc portion of IgG1, CD4-IgG2 has less potential to mediate functions such as antibody-dependent enhancement of infection or transplacental transmission of HIV-1. When tested in a virus- free HIV-1 envelope glycoprotein-mediated cell fusion assay, the tetrameric CD4-IgG2 molecule inhibited syncytium formation more effectively than monomeric sCD4 or a dimeric CD4-γ2 fusion protein. This suggests the protein will block cell-to-cell transmission of HIV-1. Moreover, CD4-IgG2 effectively neutralized a panel of laboratory-adapted strains and primary isolates of HIV-1, including strains with different tropisms and isolated from different stages of the disease, at concentrations that should be readily achieved in vivo.

Original languageEnglish (US)
Pages (from-to)533-539
Number of pages7
JournalAIDS Research and Human Retroviruses
Volume11
Issue number5
StatePublished - 1995
Externally publishedYes

Fingerprint

HIV-1
Proteins
Antibody-Dependent Enhancement
Immunoglobulin G
Viruses
CD4 Antigens
Tropism
Fc Receptors
Cell Fusion
Giant Cells
Cricetulus
Infection
CD4-IgG(2)
Half-Life
Monocytes
Ovary
Glycoproteins
Pharmacokinetics
Macrophages
Rabbits

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Allaway, G. P., Davis-Bruno, K. L., Beaudry, G. A., Garcia, E. B., Wong, E. L., Ryder, A. M., ... Maddon, P. J. (1995). Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Research and Human Retroviruses, 11(5), 533-539.

Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. / Allaway, G. P.; Davis-Bruno, K. L.; Beaudry, G. A.; Garcia, E. B.; Wong, E. L.; Ryder, A. M.; Hasel, K. W.; Gauduin, M. C.; Koup, R. A.; McDougal, J. S.; Maddon, P. J.

In: AIDS Research and Human Retroviruses, Vol. 11, No. 5, 1995, p. 533-539.

Research output: Contribution to journalArticle

Allaway, GP, Davis-Bruno, KL, Beaudry, GA, Garcia, EB, Wong, EL, Ryder, AM, Hasel, KW, Gauduin, MC, Koup, RA, McDougal, JS & Maddon, PJ 1995, 'Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates', AIDS Research and Human Retroviruses, vol. 11, no. 5, pp. 533-539.
Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Research and Human Retroviruses. 1995;11(5):533-539.
Allaway, G. P. ; Davis-Bruno, K. L. ; Beaudry, G. A. ; Garcia, E. B. ; Wong, E. L. ; Ryder, A. M. ; Hasel, K. W. ; Gauduin, M. C. ; Koup, R. A. ; McDougal, J. S. ; Maddon, P. J. / Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. In: AIDS Research and Human Retroviruses. 1995 ; Vol. 11, No. 5. pp. 533-539.
@article{f5e1e969df4c4bf785d6bc5bbd4cdf0f,
title = "Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates",
abstract = "CD4-IgG2 is a novel fusion protein comprising human IgG2 in which the Fv portions of both heavy and light chains have been replaced by the V1 and V2 domains of human CD4. This tetrameric protein is being developed as an immunoprophylactic agent to reduce the probability of infection following HIV-1 exposure, in settings such as occupational or perinatal exposure to the virus. CD4-IgG2 has been expressed in Chinese hamster ovary cells and is secreted as a fully assembled heterotetramer. The protein binds with nanomolar affinity to purified gp120 from both a laboratory-adapted strain and a primary isolate of HIV-1. Pharmacokinetic studies in rabbits demonstrated that CD4-IgG2 has a plasma terminal half-life greater than 1 day, compared with 15 min for soluble CD4 (sCD4). CD4-IgG2 does not bind to Fc receptors on the surface of U937 monocyte/macrophage cells. Compared to molecules that incorporate the Fc portion of IgG1, CD4-IgG2 has less potential to mediate functions such as antibody-dependent enhancement of infection or transplacental transmission of HIV-1. When tested in a virus- free HIV-1 envelope glycoprotein-mediated cell fusion assay, the tetrameric CD4-IgG2 molecule inhibited syncytium formation more effectively than monomeric sCD4 or a dimeric CD4-γ2 fusion protein. This suggests the protein will block cell-to-cell transmission of HIV-1. Moreover, CD4-IgG2 effectively neutralized a panel of laboratory-adapted strains and primary isolates of HIV-1, including strains with different tropisms and isolated from different stages of the disease, at concentrations that should be readily achieved in vivo.",
author = "Allaway, {G. P.} and Davis-Bruno, {K. L.} and Beaudry, {G. A.} and Garcia, {E. B.} and Wong, {E. L.} and Ryder, {A. M.} and Hasel, {K. W.} and Gauduin, {M. C.} and Koup, {R. A.} and McDougal, {J. S.} and Maddon, {P. J.}",
year = "1995",
language = "English (US)",
volume = "11",
pages = "533--539",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates

AU - Allaway, G. P.

AU - Davis-Bruno, K. L.

AU - Beaudry, G. A.

AU - Garcia, E. B.

AU - Wong, E. L.

AU - Ryder, A. M.

AU - Hasel, K. W.

AU - Gauduin, M. C.

AU - Koup, R. A.

AU - McDougal, J. S.

AU - Maddon, P. J.

PY - 1995

Y1 - 1995

N2 - CD4-IgG2 is a novel fusion protein comprising human IgG2 in which the Fv portions of both heavy and light chains have been replaced by the V1 and V2 domains of human CD4. This tetrameric protein is being developed as an immunoprophylactic agent to reduce the probability of infection following HIV-1 exposure, in settings such as occupational or perinatal exposure to the virus. CD4-IgG2 has been expressed in Chinese hamster ovary cells and is secreted as a fully assembled heterotetramer. The protein binds with nanomolar affinity to purified gp120 from both a laboratory-adapted strain and a primary isolate of HIV-1. Pharmacokinetic studies in rabbits demonstrated that CD4-IgG2 has a plasma terminal half-life greater than 1 day, compared with 15 min for soluble CD4 (sCD4). CD4-IgG2 does not bind to Fc receptors on the surface of U937 monocyte/macrophage cells. Compared to molecules that incorporate the Fc portion of IgG1, CD4-IgG2 has less potential to mediate functions such as antibody-dependent enhancement of infection or transplacental transmission of HIV-1. When tested in a virus- free HIV-1 envelope glycoprotein-mediated cell fusion assay, the tetrameric CD4-IgG2 molecule inhibited syncytium formation more effectively than monomeric sCD4 or a dimeric CD4-γ2 fusion protein. This suggests the protein will block cell-to-cell transmission of HIV-1. Moreover, CD4-IgG2 effectively neutralized a panel of laboratory-adapted strains and primary isolates of HIV-1, including strains with different tropisms and isolated from different stages of the disease, at concentrations that should be readily achieved in vivo.

AB - CD4-IgG2 is a novel fusion protein comprising human IgG2 in which the Fv portions of both heavy and light chains have been replaced by the V1 and V2 domains of human CD4. This tetrameric protein is being developed as an immunoprophylactic agent to reduce the probability of infection following HIV-1 exposure, in settings such as occupational or perinatal exposure to the virus. CD4-IgG2 has been expressed in Chinese hamster ovary cells and is secreted as a fully assembled heterotetramer. The protein binds with nanomolar affinity to purified gp120 from both a laboratory-adapted strain and a primary isolate of HIV-1. Pharmacokinetic studies in rabbits demonstrated that CD4-IgG2 has a plasma terminal half-life greater than 1 day, compared with 15 min for soluble CD4 (sCD4). CD4-IgG2 does not bind to Fc receptors on the surface of U937 monocyte/macrophage cells. Compared to molecules that incorporate the Fc portion of IgG1, CD4-IgG2 has less potential to mediate functions such as antibody-dependent enhancement of infection or transplacental transmission of HIV-1. When tested in a virus- free HIV-1 envelope glycoprotein-mediated cell fusion assay, the tetrameric CD4-IgG2 molecule inhibited syncytium formation more effectively than monomeric sCD4 or a dimeric CD4-γ2 fusion protein. This suggests the protein will block cell-to-cell transmission of HIV-1. Moreover, CD4-IgG2 effectively neutralized a panel of laboratory-adapted strains and primary isolates of HIV-1, including strains with different tropisms and isolated from different stages of the disease, at concentrations that should be readily achieved in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0029062687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029062687&partnerID=8YFLogxK

M3 - Article

C2 - 7576908

AN - SCOPUS:0029062687

VL - 11

SP - 533

EP - 539

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 5

ER -